Jerm15的个人主页 - 老虎社区

Jerm15

Jerm15

暂无个人介绍

IP属地：未知

161关注

1粉丝

0主题

0勋章

2021-12-19

Like

Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade

2021-12-17

Like

5 Stocks Insiders Are Selling

2021-12-16

Like

抱歉，原内容已删除

2021-12-15

Like

U.S. retail sales climb tepid 0.3% in November as Americans confront high inflation

2021-12-02

Like

2 Ridiculously Cheap Dividend Stocks To Buy for 2022

2021-11-03

Like

Bed Bath & Beyond jumps 85% after announcing plans to complete $1B buyback

2021-10-19

Like

Tesla and 15 Other EV Stocks Are Worth Almost as Much as 50 Traditional Car Makers. How That Makes Sense.

2021-10-16

Like

Is It Too Late to Buy Upstart Stock?

2021-10-13

Like

Apple shares fell nearly 1% in premarket trading

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3583542338461065,"uuid":"3583542338461065","gmtCreate":1620448455122,"gmtModify":1624721380003,"name":"Jerm15","pinyin":"jerm15","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/037e3a87ba0e28ca2573a2264ea74e47","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":161,"tweetSize":36,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.43%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"61.00%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":693000140,"gmtCreate":1639916996670,"gmtModify":1639916996729,"author":{"id":"3583542338461065","authorId":"3583542338461065","name":"Jerm15","avatar":"https://static.tigerbbs.com/037e3a87ba0e28ca2573a2264ea74e47","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693000140","repostId":"1122414343","repostType":4,"repost":{"id":"1122414343","pubTimestamp":1639884070,"share":"https://www.laohu8.com/m/news/1122414343?lang=&edition=full","pubTime":"2021-12-19 11:21","market":"us","language":"en","title":"Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade","url":"https://stock-news.laohu8.com/highlight/detail?id=1122414343","media":"Seeking Alpha","summary":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5","content":"<p>The healthcare stocks in the S&amp;P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&amp;A prospects. <a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.</p>\n<p>Among stocks with more than $2B market capitalization and 100K average daily volume over the past week, <a href=\"https://laohu8.com/S/ARNA\">Arena Pharmaceuticals </a> dominated with a ~83.8% rise after <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. <a href=\"https://laohu8.com/S/CERN\">Cerner </a> also joined the M&amp;A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from <a href=\"https://laohu8.com/S/ORCL\">Oracle </a> for the electronic-medical-records company.</p>\n<p>Vaccine developer, <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.</p>\n<p><a href=\"https://laohu8.com/S/BHVN\">Biohaven Pharmaceutical </a> posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, <a href=\"https://laohu8.com/S/ROIV\">Roivant Sciences </a> added ~22.6%.</p>\n<p>Notable gainer: <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the <a href=\"https://laohu8.com/S/NWY\">New York</a>-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.</p>\n<p>Among worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.</p>\n<p>Last week’s best performer, <a href=\"https://laohu8.com/S/BHG\">Bright Health Group</a>, crashed ~13.1%, hurt by the sole Sell rating issued by <a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a> even as the investment bank kicked off its coverage on managed care with largely positive views.</p>\n<p>Allogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic <a href=\"https://laohu8.com/S/00699\">CAR</a> T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax, Vir among healthcare gainers, Pfizer posts best rally in a decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-19 11:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the ...</p>\n\n<a href=\"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ORCL":"甲骨文","BK4534":"瑞士信贷持仓","CERN":"美国塞纳","BK4568":"美国抗疫概念","ARNA":"阿里那","PFE":"辉瑞","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药"},"source_url":"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122414343","content_text":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.\nAmong stocks with more than $2B market capitalization and 100K average daily volume over the past week, Arena Pharmaceuticals  dominated with a ~83.8% rise after Pfizer  agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. Cerner  also joined the M&A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from Oracle  for the electronic-medical-records company.\nVaccine developer, Novavax  jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.\nBiohaven Pharmaceutical  posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, Roivant Sciences  added ~22.6%.\nNotable gainer: Pfizer (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the New York-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.\nAmong worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.\nLast week’s best performer, Bright Health Group, crashed ~13.1%, hurt by the sole Sell rating issued by Goldman Sachs even as the investment bank kicked off its coverage on managed care with largely positive views.\nAllogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic CAR T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.","news_type":1},"isVote":1,"tweetType":1,"viewCount":418,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699336409,"gmtCreate":1639747717246,"gmtModify":1639747717246,"author":{"id":"3583542338461065","authorId":"3583542338461065","name":"Jerm15","avatar":"https://static.tigerbbs.com/037e3a87ba0e28ca2573a2264ea74e47","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699336409","repostId":"1116116501","repostType":4,"repost":{"id":"1116116501","pubTimestamp":1639745427,"share":"https://www.laohu8.com/m/news/1116116501?lang=&edition=full","pubTime":"2021-12-17 20:50","market":"us","language":"en","title":"5 Stocks Insiders Are Selling","url":"https://stock-news.laohu8.com/highlight/detail?id=1116116501","media":"Benzinga","summary":"When insiders sell shares, it indicates their concern in the company’s prospects or that they view t","content":"<p>When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.</p>\n<p>Below is a look at a few recent notable insider sales.</p>\n<p><b>LegalZoom.com</b></p>\n<ul>\n <li><b>The Trade:LegalZoom.com, Inc.</b>&nbsp;Chief Financial Officer Bertram Noel Watson&nbsp;<i>disposed a total of 69466 shares</i>&nbsp;at an average price of $15.65. The insider received $1,087,351.30 as a result of the transaction.</li>\n <li><b>What’s Happening:</b>Morgan Stanley maintained LegalZoom.com with an Equal-Weight and lowered the price target from $28 to $19.</li>\n <li><b>What LegalZoom.com Does:</b>LegalZoom.com Inc is an online provider of services that meet the legal needs of small businesses and consumers in the United States</li>\n</ul>\n<p><b>Arvinas</b></p>\n<ul>\n <li><b>The Trade:Arvinas, Inc.</b>&nbsp;Director Liam Ratcliffe&nbsp;<i>sold a total of 355705 shares</i>&nbsp;at an average price of $67.00. The insider received $23,833,380.68 from selling those shares.</li>\n <li><b>What’s Happening:</b>Arvinas and Pfizer recently posted updated data from Phase 1 dose-escalation trial of ARV-471 for locally advanced or metastatic ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (ER+/HER2-).</li>\n <li><b>What Arvinas Does:</b>Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases.</li>\n</ul>\n<p><b>Marvell Technology</b></p>\n<ul>\n <li><b>The Trade:Marvell Technology, Inc.</b>&nbsp;CEO and President Matthew Murphy&nbsp;<i>sold a total of 30000 shares</i>&nbsp;at an average price of $85.98. The insider received $2,579,400.00 as a result of the transaction.</li>\n <li><b>What’s Happening:</b>Marvell recently introduced industry's first 50G PAM4 DSP chipset for next generation 5G RAN optical fronthaul.</li>\n <li><b>What Marvell Technology Does:</b>Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications.</li>\n</ul>\n<p><b>Hewlett Packard Enterprise</b></p>\n<ul>\n <li><b>The Trade:Hewlett Packard Enterprise Company</b>&nbsp;SVP &amp; GM, HPC &amp; AI Business Group Justin Hotard&nbsp;<i>sold a total of 40012 shares</i>&nbsp;at an average price of $14.55. The insider received $582,174.60 from selling those shares.</li>\n <li><b>What’s Happening:</b>Hewlett Packard Enterprise recently reported worse-than-expected Q4 sales results.</li>\n <li><b>What Hewlett Packard Enterprise Does:</b>Hewlett Packard Enterprise is a supplier of IT infrastructure products and services. The company operates as three major segments.</li>\n</ul>\n<p><b>Ameren</b></p>\n<ul>\n <li><b>The Trade:Ameren Corporation</b>&nbsp;Chairman, President and CEO Warner L Baxter<i>sold a total of 68300 shares</i>&nbsp;at an average price of $87.31. The insider received $4,976,670.00 from selling those shares.</li>\n <li><b>What’s Happening:</b>BMO Capital recently maintained Ameren with an Outperform and raised the price target from $85 to $95.</li>\n <li><b>What Ameren Does:</b>Ameren owns rate-regulated generation, transmission, and distribution networks that deliver electricity and natural gas in Missouri and Illinois. It serves nearly 2.5 million electricity customers and roughly 1.0 million natural gas customers.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks Insiders Are Selling</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks Insiders Are Selling\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/21/12/24666623/5-stocks-insiders-are-selling><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. ...</p>\n\n<a href=\"https://www.benzinga.com/news/21/12/24666623/5-stocks-insiders-are-selling\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRVL":"迈威尔科技","AEE":"阿曼瑞恩","HPE":"慧与科技","LZ":"LegalZoom.com, Inc","ARVN":"Arvinas Holding Company LLC"},"source_url":"https://www.benzinga.com/news/21/12/24666623/5-stocks-insiders-are-selling","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116116501","content_text":"When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.\nBelow is a look at a few recent notable insider sales.\nLegalZoom.com\n\nThe Trade:LegalZoom.com, Inc. Chief Financial Officer Bertram Noel Watson disposed a total of 69466 shares at an average price of $15.65. The insider received $1,087,351.30 as a result of the transaction.\nWhat’s Happening:Morgan Stanley maintained LegalZoom.com with an Equal-Weight and lowered the price target from $28 to $19.\nWhat LegalZoom.com Does:LegalZoom.com Inc is an online provider of services that meet the legal needs of small businesses and consumers in the United States\n\nArvinas\n\nThe Trade:Arvinas, Inc. Director Liam Ratcliffe sold a total of 355705 shares at an average price of $67.00. The insider received $23,833,380.68 from selling those shares.\nWhat’s Happening:Arvinas and Pfizer recently posted updated data from Phase 1 dose-escalation trial of ARV-471 for locally advanced or metastatic ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (ER+/HER2-).\nWhat Arvinas Does:Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases.\n\nMarvell Technology\n\nThe Trade:Marvell Technology, Inc. CEO and President Matthew Murphy sold a total of 30000 shares at an average price of $85.98. The insider received $2,579,400.00 as a result of the transaction.\nWhat’s Happening:Marvell recently introduced industry's first 50G PAM4 DSP chipset for next generation 5G RAN optical fronthaul.\nWhat Marvell Technology Does:Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications.\n\nHewlett Packard Enterprise\n\nThe Trade:Hewlett Packard Enterprise Company SVP & GM, HPC & AI Business Group Justin Hotard sold a total of 40012 shares at an average price of $14.55. The insider received $582,174.60 from selling those shares.\nWhat’s Happening:Hewlett Packard Enterprise recently reported worse-than-expected Q4 sales results.\nWhat Hewlett Packard Enterprise Does:Hewlett Packard Enterprise is a supplier of IT infrastructure products and services. The company operates as three major segments.\n\nAmeren\n\nThe Trade:Ameren Corporation Chairman, President and CEO Warner L Baxtersold a total of 68300 shares at an average price of $87.31. The insider received $4,976,670.00 from selling those shares.\nWhat’s Happening:BMO Capital recently maintained Ameren with an Outperform and raised the price target from $85 to $95.\nWhat Ameren Does:Ameren owns rate-regulated generation, transmission, and distribution networks that deliver electricity and natural gas in Missouri and Illinois. It serves nearly 2.5 million electricity customers and roughly 1.0 million natural gas customers.","news_type":1},"isVote":1,"tweetType":1,"viewCount":372,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690938709,"gmtCreate":1639620105596,"gmtModify":1639620241947,"author":{"id":"3583542338461065","authorId":"3583542338461065","name":"Jerm15","avatar":"https://static.tigerbbs.com/037e3a87ba0e28ca2573a2264ea74e47","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690938709","repostId":"1139620589","repostType":4,"isVote":1,"tweetType":1,"viewCount":536,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607427370,"gmtCreate":1639580437231,"gmtModify":1639580437308,"author":{"id":"3583542338461065","authorId":"3583542338461065","name":"Jerm15","avatar":"https://static.tigerbbs.com/037e3a87ba0e28ca2573a2264ea74e47","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607427370","repostId":"1148643584","repostType":4,"repost":{"id":"1148643584","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639575903,"share":"https://www.laohu8.com/m/news/1148643584?lang=&edition=full","pubTime":"2021-12-15 21:45","market":"us","language":"en","title":"U.S. retail sales climb tepid 0.3% in November as Americans confront high inflation ","url":"https://stock-news.laohu8.com/highlight/detail?id=1148643584","media":"Tiger Newspress","summary":"The numbers: Amazon, Target and other retailers posted a small 0.3% increase in sales in November at","content":"<p><b>The numbers:</b> Amazon, Target and other retailers posted a small 0.3% increase in sales in November at the start of the holiday season, but if high inflation is taken into account, receipts fell in a weak showing for the economy.</p>\n<p></p>\n<p>Economists polled by The Wall Street Journal had forecast a 0.8% increase.</p>\n<p>The increase in sales was outstripped by a rising cost of living. The consumer price index jumped 0.8% in November to push the yearly&nbsp;rate of inflation to a 39-year high of 6.8%<a href=\"https://www.marketwatch.com/story/americans-pay-the-price-for-high-inflation-each-time-they-go-to-the-grocery-store-11639155038?mod=economic-report&amp;mod=article_inline\" target=\"_blank\">.</a> Adjusted for inflation retail sales appeared to have declined.</p>\n<p><b>Big picture:</b> Americans have lots to spend because of stimulus money, rising wages and high savings amassed during the pandemic. But surging inflation might make them rethink what they buy.</p>\n<p>The big danger is if high inflation persists and price increases become embedded in the economy. That could force the Federal Reserve to jack up interest rates, further raise business costs and discourage consumers from buying as many goods and services.</p>\n<p>The Fed still believes inflation will cool off in 2022, but the central bank is worried enough to phase out stimulus for the economy a lot faster than it had planned.</p>\n<p><b>Market reaction:</b>&nbsp;The Dow Jones Industrial Average&nbsp;and S&amp;P 500 were set to open slightly lower in Wednesday trades.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. retail sales climb tepid 0.3% in November as Americans confront high inflation </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. retail sales climb tepid 0.3% in November as Americans confront high inflation \n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-15 21:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>The numbers:</b> Amazon, Target and other retailers posted a small 0.3% increase in sales in November at the start of the holiday season, but if high inflation is taken into account, receipts fell in a weak showing for the economy.</p>\n<p></p>\n<p>Economists polled by The Wall Street Journal had forecast a 0.8% increase.</p>\n<p>The increase in sales was outstripped by a rising cost of living. The consumer price index jumped 0.8% in November to push the yearly&nbsp;rate of inflation to a 39-year high of 6.8%<a href=\"https://www.marketwatch.com/story/americans-pay-the-price-for-high-inflation-each-time-they-go-to-the-grocery-store-11639155038?mod=economic-report&amp;mod=article_inline\" target=\"_blank\">.</a> Adjusted for inflation retail sales appeared to have declined.</p>\n<p><b>Big picture:</b> Americans have lots to spend because of stimulus money, rising wages and high savings amassed during the pandemic. But surging inflation might make them rethink what they buy.</p>\n<p>The big danger is if high inflation persists and price increases become embedded in the economy. That could force the Federal Reserve to jack up interest rates, further raise business costs and discourage consumers from buying as many goods and services.</p>\n<p>The Fed still believes inflation will cool off in 2022, but the central bank is worried enough to phase out stimulus for the economy a lot faster than it had planned.</p>\n<p><b>Market reaction:</b>&nbsp;The Dow Jones Industrial Average&nbsp;and S&amp;P 500 were set to open slightly lower in Wednesday trades.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148643584","content_text":"The numbers: Amazon, Target and other retailers posted a small 0.3% increase in sales in November at the start of the holiday season, but if high inflation is taken into account, receipts fell in a weak showing for the economy.\n\nEconomists polled by The Wall Street Journal had forecast a 0.8% increase.\nThe increase in sales was outstripped by a rising cost of living. The consumer price index jumped 0.8% in November to push the yearly rate of inflation to a 39-year high of 6.8%. Adjusted for inflation retail sales appeared to have declined.\nBig picture: Americans have lots to spend because of stimulus money, rising wages and high savings amassed during the pandemic. But surging inflation might make them rethink what they buy.\nThe big danger is if high inflation persists and price increases become embedded in the economy. That could force the Federal Reserve to jack up interest rates, further raise business costs and discourage consumers from buying as many goods and services.\nThe Fed still believes inflation will cool off in 2022, but the central bank is worried enough to phase out stimulus for the economy a lot faster than it had planned.\nMarket reaction: The Dow Jones Industrial Average and S&P 500 were set to open slightly lower in Wednesday trades.","news_type":1},"isVote":1,"tweetType":1,"viewCount":433,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603245862,"gmtCreate":1638418618759,"gmtModify":1638418618874,"author":{"id":"3583542338461065","authorId":"3583542338461065","name":"Jerm15","avatar":"https://static.tigerbbs.com/037e3a87ba0e28ca2573a2264ea74e47","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603245862","repostId":"1182613816","repostType":4,"repost":{"id":"1182613816","pubTimestamp":1638415076,"share":"https://www.laohu8.com/m/news/1182613816?lang=&edition=full","pubTime":"2021-12-02 11:17","market":"us","language":"en","title":"2 Ridiculously Cheap Dividend Stocks To Buy for 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1182613816","media":"Motley Fool","summary":"The S&P 500had its worst day of the year on Friday, falling 900 points on the news that there could ","content":"<p>The&nbsp;<b>S&amp;P 500</b>had its worst day of the year on Friday, falling 900 points on the news that there could be a new obstacle in the economy's recovery: omicron, the latest COVID-19 variant.</p>\n<p>For investors looking to get away from this volatility and find more safety, holding dividend stocks in your portfolio can be an excellent decision. They can ensure that you're collecting a recurring stream of income you can use to help offset losses in your portfolio. And at best, they can boost your returns. Two dividend stocks that pay an above-average yield and are incredibly cheap right now are&nbsp;<b>AbbVie</b>(NYSE:ABBV)and&nbsp;<b>ViacomCBS</b>(NASDAQ:VIAC).</p>\n<p>1. AbbVie</p>\n<p>AbbVie makes for an ideal buy-and-forget investment. The&nbsp;healthcare stock&nbsp;yields an impressive 4.8% right now -- well above the&nbsp;<b>S&amp;P 500</b>average of just 1.4%. And the dividend is well supported; in the past 12 months, the company has generated free cash flow of $21.7 billion, more than double the $9 billion in dividends it paid out during that time.</p>\n<p>When the company released its latest quarterly earnings results on Oct. 29, it reported sales of $14.3 billion, 11% higher than the year-ago period. The company also raised its guidance for a third time in 2021, anticipating that its adjusted diluted earnings per share will come in between $12.63 and $12.67 for the full year. That's well above the $5.64 in dividends that the company is paying out annually per share. TheDividend Aristocratalso raised its dividend by 8.5% in a hike that will come into effect next year.</p>\n<p>While investors may be worried about the company's expiring patent on rhe&nbsp;umatoid arthritis drug Humira, AbbVie's management anticipates that newer drugs like Skyrizi and Rinvoq will generate long-term growth and make up for the inevitable decline in Humira's sales. Both drugs still have a long way to go. In just the latest quarter, they achieved combined sales of $1.2 billion in sales while Humira brought in more than $5.4 billion.</p>\n<p>CEO Richard Gonzalez said, \"What we're basically trying to accomplish with the company is build a set of assets that could ultimately significantly replace Humira in the marketplace and be superior to Humira.\"</p>\n<p>Even if there's a dip in profitability, AbbVie has plenty of room to support its dividend. And with other pharma stocks like&nbsp;<b>Pfizer</b>,<b>Merck</b>, and&nbsp;<b>Amgen</b>&nbsp;trading at forward&nbsp;price-to-earnings(P/E) multiples of more than 12, AbbVie's multiple of nine makes the stock look like a bargain buy.</p>\n<p>2. ViacomCBS</p>\n<p>Media and entertainment company ViacomCBS pays a dividend that currently yields right around 3% per year. While it's not as high as AbbVie's payout, the stock could more than make up for that with some possibly stronger gains. Viacom currently trades at a forward P/E of less than nine, which is dirt cheap as streaming stocks&nbsp;<b>WaltDisney</b>&nbsp;and&nbsp;<b>Netflix</b>&nbsp;trade at multiples of 35 and 62, respectively.</p>\n<p>One of the reasons investors aren't as bullish on ViacomCBS is that it still isn't a big rival to those streaming giants. At 47 million global streaming subscribers across its services (including Paramount+), ViacomCBS is nowhere near Netflix's tally of 214 million and has a long way to go in catching up to Disney at over 118 million.</p>\n<p>Plus, ViacomCBS's streaming service isn't even the biggest part of its business. In the latest quarter, its advertising, affiliate, and licensing segments together contributed the vast majority of the company's revenue -- about $5.5 billion in all. However, this latest quarter marked the first time that its global streaming revenue surpassed $1 billion. And with revenue growth of 72% over the year-ago period, streaming is by far the company's fastest-growing segment.</p>\n<p>Although it may not be as popular as its bigger-name rivals, ViacomCBS is posting some strong results of late and it could be an&nbsp;attractive contrarian betto take. Plus, its dividend makes it an even better buy.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Ridiculously Cheap Dividend Stocks To Buy for 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Ridiculously Cheap Dividend Stocks To Buy for 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-02 11:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/01/2-ridiculously-cheap-dividend-stocks-to-buy-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500had its worst day of the year on Friday, falling 900 points on the news that there could be a new obstacle in the economy's recovery: omicron, the latest COVID-19 variant.\nFor investors ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/01/2-ridiculously-cheap-dividend-stocks-to-buy-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2021/12/01/2-ridiculously-cheap-dividend-stocks-to-buy-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182613816","content_text":"The S&P 500had its worst day of the year on Friday, falling 900 points on the news that there could be a new obstacle in the economy's recovery: omicron, the latest COVID-19 variant.\nFor investors looking to get away from this volatility and find more safety, holding dividend stocks in your portfolio can be an excellent decision. They can ensure that you're collecting a recurring stream of income you can use to help offset losses in your portfolio. And at best, they can boost your returns. Two dividend stocks that pay an above-average yield and are incredibly cheap right now are AbbVie(NYSE:ABBV)and ViacomCBS(NASDAQ:VIAC).\n1. AbbVie\nAbbVie makes for an ideal buy-and-forget investment. The healthcare stock yields an impressive 4.8% right now -- well above the S&P 500average of just 1.4%. And the dividend is well supported; in the past 12 months, the company has generated free cash flow of $21.7 billion, more than double the $9 billion in dividends it paid out during that time.\nWhen the company released its latest quarterly earnings results on Oct. 29, it reported sales of $14.3 billion, 11% higher than the year-ago period. The company also raised its guidance for a third time in 2021, anticipating that its adjusted diluted earnings per share will come in between $12.63 and $12.67 for the full year. That's well above the $5.64 in dividends that the company is paying out annually per share. TheDividend Aristocratalso raised its dividend by 8.5% in a hike that will come into effect next year.\nWhile investors may be worried about the company's expiring patent on rhe umatoid arthritis drug Humira, AbbVie's management anticipates that newer drugs like Skyrizi and Rinvoq will generate long-term growth and make up for the inevitable decline in Humira's sales. Both drugs still have a long way to go. In just the latest quarter, they achieved combined sales of $1.2 billion in sales while Humira brought in more than $5.4 billion.\nCEO Richard Gonzalez said, \"What we're basically trying to accomplish with the company is build a set of assets that could ultimately significantly replace Humira in the marketplace and be superior to Humira.\"\nEven if there's a dip in profitability, AbbVie has plenty of room to support its dividend. And with other pharma stocks like Pfizer,Merck, and Amgen trading at forward price-to-earnings(P/E) multiples of more than 12, AbbVie's multiple of nine makes the stock look like a bargain buy.\n2. ViacomCBS\nMedia and entertainment company ViacomCBS pays a dividend that currently yields right around 3% per year. While it's not as high as AbbVie's payout, the stock could more than make up for that with some possibly stronger gains. Viacom currently trades at a forward P/E of less than nine, which is dirt cheap as streaming stocks WaltDisney and Netflix trade at multiples of 35 and 62, respectively.\nOne of the reasons investors aren't as bullish on ViacomCBS is that it still isn't a big rival to those streaming giants. At 47 million global streaming subscribers across its services (including Paramount+), ViacomCBS is nowhere near Netflix's tally of 214 million and has a long way to go in catching up to Disney at over 118 million.\nPlus, ViacomCBS's streaming service isn't even the biggest part of its business. In the latest quarter, its advertising, affiliate, and licensing segments together contributed the vast majority of the company's revenue -- about $5.5 billion in all. However, this latest quarter marked the first time that its global streaming revenue surpassed $1 billion. And with revenue growth of 72% over the year-ago period, streaming is by far the company's fastest-growing segment.\nAlthough it may not be as popular as its bigger-name rivals, ViacomCBS is posting some strong results of late and it could be an attractive contrarian betto take. Plus, its dividend makes it an even better buy.","news_type":1},"isVote":1,"tweetType":1,"viewCount":838,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841511031,"gmtCreate":1635924404437,"gmtModify":1635924404437,"author":{"id":"3583542338461065","authorId":"3583542338461065","name":"Jerm15","avatar":"https://static.tigerbbs.com/037e3a87ba0e28ca2573a2264ea74e47","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841511031","repostId":"1127572635","repostType":4,"repost":{"id":"1127572635","pubTimestamp":1635900782,"share":"https://www.laohu8.com/m/news/1127572635?lang=&edition=full","pubTime":"2021-11-03 08:53","market":"us","language":"en","title":"Bed Bath & Beyond jumps 85% after announcing plans to complete $1B buyback","url":"https://stock-news.laohu8.com/highlight/detail?id=1127572635","media":"seekingalpha","summary":"Bed Bath & Beyond(NASDAQ:BBBY)expects to complete its $1B three-year share repurchase plan by the en","content":"<p>Bed Bath &amp; Beyond(NASDAQ:BBBY)expects to complete its&nbsp;$1B three-year share repurchase plan by the end of fiscal 2021, two years ahead of schedule.</p>\n<p>Company has completed $600M in share repurchases since the end of fiscal 2020.</p>\n<p>Now expects to repurchase the remaining $400M by the end of fiscal 2021, specifically over the Q3 and Q4.</p>\n<p><img src=\"https://static.tigerbbs.com/026a90f97d75035beaf8d2b91bb8ced5\" tg-width=\"663\" tg-height=\"265\" width=\"100%\" height=\"auto\"></p>\n<p>Mark Tritton,&nbsp;President and CEO commented, \"As we continue to navigate the third quarter, the corrective and surgical pricing actions we've implemented are resulting in a trend toward expected gross margin rates for the period.&nbsp; Sales to date have remained consistent with the September trends we shared on our earnings call several weeks ago.&nbsp; Our focus remains on delivering comp sales growth in the all-important November month, which represents a disproportionately larger impact to our quarterly sales.&nbsp; We are preparing for the peak Holiday season and are particularly excited about the new future sales channels that we've announced today, which are our strategic collaboration with Kroger and our own digital Marketplace.\"</p>\n<p>Shares&nbsp;jump 85%&nbsp;during post-market hours to $16.75.</p>\n<p>Bullish commentary on the stock by contributors who write: 'The Customer-Inspired Strategy Based On Data Analysts Makes Bed Bath &amp; Beyond A Buy' and 'Bed Bath &amp; Beyond: Deeply Undervalued (If Transformation Is Successful)'</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bed Bath & Beyond jumps 85% after announcing plans to complete $1B buyback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBed Bath & Beyond jumps 85% after announcing plans to complete $1B buyback\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-03 08:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3763452-bed-bath-beyond-flies-whopping-85-plans-to-complete-1b-buyback-by-the-end-of-fy2021><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bed Bath & Beyond(NASDAQ:BBBY)expects to complete its $1B three-year share repurchase plan by the end of fiscal 2021, two years ahead of schedule.\nCompany has completed $600M in share repurchases ...</p>\n\n<a href=\"https://seekingalpha.com/news/3763452-bed-bath-beyond-flies-whopping-85-plans-to-complete-1b-buyback-by-the-end-of-fy2021\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BBBY":"3B家居"},"source_url":"https://seekingalpha.com/news/3763452-bed-bath-beyond-flies-whopping-85-plans-to-complete-1b-buyback-by-the-end-of-fy2021","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1127572635","content_text":"Bed Bath & Beyond(NASDAQ:BBBY)expects to complete its $1B three-year share repurchase plan by the end of fiscal 2021, two years ahead of schedule.\nCompany has completed $600M in share repurchases since the end of fiscal 2020.\nNow expects to repurchase the remaining $400M by the end of fiscal 2021, specifically over the Q3 and Q4.\n\nMark Tritton, President and CEO commented, \"As we continue to navigate the third quarter, the corrective and surgical pricing actions we've implemented are resulting in a trend toward expected gross margin rates for the period.  Sales to date have remained consistent with the September trends we shared on our earnings call several weeks ago.  Our focus remains on delivering comp sales growth in the all-important November month, which represents a disproportionately larger impact to our quarterly sales.  We are preparing for the peak Holiday season and are particularly excited about the new future sales channels that we've announced today, which are our strategic collaboration with Kroger and our own digital Marketplace.\"\nShares jump 85% during post-market hours to $16.75.\nBullish commentary on the stock by contributors who write: 'The Customer-Inspired Strategy Based On Data Analysts Makes Bed Bath & Beyond A Buy' and 'Bed Bath & Beyond: Deeply Undervalued (If Transformation Is Successful)'","news_type":1},"isVote":1,"tweetType":1,"viewCount":368,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":850719551,"gmtCreate":1634626340644,"gmtModify":1634626340783,"author":{"id":"3583542338461065","authorId":"3583542338461065","name":"Jerm15","avatar":"https://static.tigerbbs.com/037e3a87ba0e28ca2573a2264ea74e47","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850719551","repostId":"1147398025","repostType":4,"repost":{"id":"1147398025","pubTimestamp":1634608414,"share":"https://www.laohu8.com/m/news/1147398025?lang=&edition=full","pubTime":"2021-10-19 09:53","market":"us","language":"en","title":"Tesla and 15 Other EV Stocks Are Worth Almost as Much as 50 Traditional Car Makers. How That Makes Sense.","url":"https://stock-news.laohu8.com/highlight/detail?id=1147398025","media":"Barrons","summary":"Tesla and other electric-vehicle makers account for almost half of the value wrapped up in car-manuf","content":"<p>Tesla&nbsp;and other electric-vehicle makers account for almost half of the value wrapped up in car-manufacturer stocks. Does that make sense?</p>\n<p>Monday, Bernstein analyst Toni Sacconaghi asked that question. He’s a&nbsp;Tesla&nbsp;(ticker: TSLA) bear—rating shares Sell with a $300 price target—mainly because he believes the stock is pricey. Still, EVs can be worth half of the industry if investors buy into three ideas.</p>\n<p>Today, 16 EV makers—including Tesla and yet-to-be public Rivian—are worth a combined $1.14 trillion. Tesla accounts for 74% of total EV value. Four of the top 10 most valuable auto makers are EV companies including: Tesla, Rivian,BYD&nbsp;(1211.Hong Kong), and&nbsp;NIO&nbsp;(NIO).</p>\n<p>As for the makers of conventional vehicles, more than 50 auto makers are worth a combined $1.42 trillion. The most valuable traditional car companies are:Toyota Motor&nbsp;(TM),Volkswagen&nbsp;(VOW3.Germany),Daimler&nbsp;(DAI.Germany), and&nbsp;General Motors&nbsp;(GM).</p>\n<p>Sales by the traditional companies still dominates unit volume, selling about 99% of the cars globally—97% of those are gasoline-powered, and 2% are EV. The EV pure-plays sell the remaining 1% worldwide.</p>\n<p>“The thinking, of course, is that pure-play EV vendors will ultimately come to dominate the automotive world,” wrote Sacconaghi in a Monday report.</p>\n<p>That’s the first thing investors need to believe to justify EV valuations. Sacconaghi points out that 2014 pure-play EV companies accounted for 14% of electric-car sales. That’s 28% today. Pure-play EV companies’ market share is growing.</p>\n<p>That’s the second belief required to stay bullish on EV makers’ stocks—that market share will continue to improve. “We suspect the market believes …that traditional OEMs will not be able to deliver competitive EV offerings in the future,” adds the analyst in his report. OEM is short for original equipment manufacturer, industry jargon for auto maker.</p>\n<p>The final thing investors need to believe is that EVs will be more profitable, per car, than conventional vehicles. EV companies tend to sell direct—which can help profitability. EV makers are also the leaders in selling add-on subscription based services. Tesla’s Full Self-Driving Capability, or FSD, is probably the best example. Tesla sells the higher levels of its autonomous-driving software as a monthly subscription or for $10,000.</p>\n<p>The mix of volume and profit growth driven by superior products could justify valuations, but Sacconaghi isn’t a believer. “Our contention is that the automotive industry is an increasingly global and hypercompetitive industry and we believe that surplus profits and technology innovation will likely be competed away over time.”</p>\n<p>His views of the industry is one of the reasons he calls Tesla valuation “too rich.”</p>\n<p>Time will tell who is right. Sacconaghi’s target price still implies Tesla should be the world’s most valuable car company, just not two to three times the value of Toyota.</p>\n<p>Tesla stock has been on a tear of late, adding 34% over the past three months as investors have become more bullish about third quarter earnings due out on Wednesday evening. Shares have gained another 3.2% Monday.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla and 15 Other EV Stocks Are Worth Almost as Much as 50 Traditional Car Makers. How That Makes Sense.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla and 15 Other EV Stocks Are Worth Almost as Much as 50 Traditional Car Makers. How That Makes Sense.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 09:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/tesla-stock-nio-51634569822?mod=hp_DAY_6><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tesla and other electric-vehicle makers account for almost half of the value wrapped up in car-manufacturer stocks. Does that make sense?\nMonday, Bernstein analyst Toni Sacconaghi asked that question....</p>\n\n<a href=\"https://www.barrons.com/articles/tesla-stock-nio-51634569822?mod=hp_DAY_6\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VLKAF":"Volkswagen AG","01211":"比亚迪股份","NIO":"蔚来","TSLA":"特斯拉","DDAIF":"戴姆勒汽车","XPEV":"小鹏汽车","LI":"理想汽车","GM":"通用汽车","TM":"丰田汽车"},"source_url":"https://www.barrons.com/articles/tesla-stock-nio-51634569822?mod=hp_DAY_6","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147398025","content_text":"Tesla and other electric-vehicle makers account for almost half of the value wrapped up in car-manufacturer stocks. Does that make sense?\nMonday, Bernstein analyst Toni Sacconaghi asked that question. He’s a Tesla (ticker: TSLA) bear—rating shares Sell with a $300 price target—mainly because he believes the stock is pricey. Still, EVs can be worth half of the industry if investors buy into three ideas.\nToday, 16 EV makers—including Tesla and yet-to-be public Rivian—are worth a combined $1.14 trillion. Tesla accounts for 74% of total EV value. Four of the top 10 most valuable auto makers are EV companies including: Tesla, Rivian,BYD (1211.Hong Kong), and NIO (NIO).\nAs for the makers of conventional vehicles, more than 50 auto makers are worth a combined $1.42 trillion. The most valuable traditional car companies are:Toyota Motor (TM),Volkswagen (VOW3.Germany),Daimler (DAI.Germany), and General Motors (GM).\nSales by the traditional companies still dominates unit volume, selling about 99% of the cars globally—97% of those are gasoline-powered, and 2% are EV. The EV pure-plays sell the remaining 1% worldwide.\n“The thinking, of course, is that pure-play EV vendors will ultimately come to dominate the automotive world,” wrote Sacconaghi in a Monday report.\nThat’s the first thing investors need to believe to justify EV valuations. Sacconaghi points out that 2014 pure-play EV companies accounted for 14% of electric-car sales. That’s 28% today. Pure-play EV companies’ market share is growing.\nThat’s the second belief required to stay bullish on EV makers’ stocks—that market share will continue to improve. “We suspect the market believes …that traditional OEMs will not be able to deliver competitive EV offerings in the future,” adds the analyst in his report. OEM is short for original equipment manufacturer, industry jargon for auto maker.\nThe final thing investors need to believe is that EVs will be more profitable, per car, than conventional vehicles. EV companies tend to sell direct—which can help profitability. EV makers are also the leaders in selling add-on subscription based services. Tesla’s Full Self-Driving Capability, or FSD, is probably the best example. Tesla sells the higher levels of its autonomous-driving software as a monthly subscription or for $10,000.\nThe mix of volume and profit growth driven by superior products could justify valuations, but Sacconaghi isn’t a believer. “Our contention is that the automotive industry is an increasingly global and hypercompetitive industry and we believe that surplus profits and technology innovation will likely be competed away over time.”\nHis views of the industry is one of the reasons he calls Tesla valuation “too rich.”\nTime will tell who is right. Sacconaghi’s target price still implies Tesla should be the world’s most valuable car company, just not two to three times the value of Toyota.\nTesla stock has been on a tear of late, adding 34% over the past three months as investors have become more bullish about third quarter earnings due out on Wednesday evening. Shares have gained another 3.2% Monday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":599,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":827923049,"gmtCreate":1634393205516,"gmtModify":1634393205661,"author":{"id":"3583542338461065","authorId":"3583542338461065","name":"Jerm15","avatar":"https://static.tigerbbs.com/037e3a87ba0e28ca2573a2264ea74e47","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/827923049","repostId":"2175485551","repostType":4,"repost":{"id":"2175485551","pubTimestamp":1634310655,"share":"https://www.laohu8.com/m/news/2175485551?lang=&edition=full","pubTime":"2021-10-15 23:10","market":"us","language":"en","title":"Is It Too Late to Buy Upstart Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2175485551","media":"Motley Fool","summary":"This company is changing how lenders gauge people's creditworthiness. It has massive growth potential and the stock price reflects that.","content":"<p><b>Upstart</b> (NASDAQ:UPST) -- a company that uses artificial intelligence systems to determine would-be borrowers' creditworthiness -- has caught the attention of Wall Street and the mainstream financial media in 2021. As a result, the stock price has surged more than 1,000% since its December 2020 IPO, raising questions about how much bigger this company can get.</p>\n<p>But investors considering buying in on Upstart now should remember that this is still a young business, and its stock has the potential to grow another 1,000% over the next decade. The company has just started de-risking itself, making it safer for investors to get a piece of the action.</p>\n<p>Let's go into more detail about why Upstart is still worth buying today.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F646666%2Fperson-looking-at-a-clear-whiteboard-thinking.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Upstart's formula could replace FICO</h2>\n<p>For decades, the chief way banks and others have determined creditworthiness is by looking at a person's FICO score -- a metric created by <b><a href=\"https://laohu8.com/S/FICO\">Fair Isaac Corp</a>.</b> (NYSE:FICO) back in 1989. There are a host of variations based on that model now, but still, those scores have certain weaknesses -- primarily because there are plenty of people who have poor credit histories or no credit history at all, but who would nonetheless be good credit risks. Fully 80% of Americans have never defaulted on a loan payment, yet fewer than half of Americans have prime credit -- meaning that as much as 30% of the populace are potentially good people to lend money to, but might get rejected by banks making their decisions solely by looking at credit scores.</p>\n<p>Upstart looks at a much bigger picture -- everything from employment history to how applicants interact with the loan application -- and takes all of this data into account, determining each consumer's creditworthiness with impressive accuracy. An internal study by Upstart showed that all other things being equal, Upstart's evaluations led to 75% fewer defaults than when relying on traditional models.</p>\n<p>Even better, the more loan decisions it makes, the more accurate Upstart's AI should get. Each borrower it recommends lending to will either pay off their loan or default. If they default, the model will learn that customers with similar traits might also be less likely to pay off loans. That steady aggregation of new data could help it adjust its decision-making and decrease its default rate as time goes on.</p>\n<p>With Upstart, the process to get a loan is becoming much easier. The company approves an average of 27% more loans than banks do using their traditional model, while applicants get on average a 16% lower interest rate. The decision process is also quick for the customer: Upstart's AI has gotten so good that it has been able to automatically approve 71% of its applications with minimal fraud risk. Among its accepted loan applications in 2020's fourth quarter, only 0.4% later proved to be fraudulent.</p>\n<h2>Innovation is leading to success</h2>\n<p>Reinventing the loan approval process has resulted in strong financial success for Upstart. The company gave its thumbs-up to 24% of the loan applications it saw in Q2 2021, reaching a transaction volume of 287,000 loans. And loan volume increased by 69% from the first quarter.</p>\n<p>Related to the increase in loan volume, Upstart's Q2 revenue grew by 1,000% year over year, and by 60% sequentially, to $194 million. Its contribution profit -- a metric similar to gross margin -- was 50% of total revenue in Q2, up from 46% in Q1 2021.</p>\n<p>Despite being a small company in terms of revenue, Upstart is profitable. Its net income for Q2 was $37 million, an improvement from its net loss of $6 million in the prior-year quarter. The company also produced free cash flow of $134 million in the first half of 2021 -- representing a free cash flow margin of 44%.</p>\n<p>It won't be surprising to see this strong growth continue. In addition to the network effects it benefits from, lending is an enormous market. Management sees a market opportunity of $635 billion in auto loan origination and an $84 billion opportunity in personal loans. It's just beginning to tap into the vehicle loan market with its recently launched Upstart Auto Retail product -- an outgrowth of the company's April acquisition of Prodigy, a provider of cloud-based software for auto sales.</p>\n<h2>Lenders are flocking to Upstart</h2>\n<p>Lenders are moving to Upstart's platform fast -- four banks have partnered with it since its Q2 report. Its customer concentration was high at the beginning of 2021, with <a href=\"https://laohu8.com/S/AONE.U\">one</a> lender accounting for 67% of its loan volume in 2020. That client only represented 60% of Upstart's loan volume in the first half, however. With the addition of these new banks since it reported Q2 earnings, its concentration figure will likely continue to decline.</p>\n<p>The stock is trading at 133 times free cash flow and 64 times sales. However, Upstart has been doing everything right so far in 2021: It has decreased its client concentration, expanded into a big new market, and rapidly grown its business. Yet it still has plenty of room for explosive growth over the next 10 years, and investors still have the opportunity to benefit from its game-changing technology.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Too Late to Buy Upstart Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Too Late to Buy Upstart Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-15 23:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/15/is-it-too-late-to-buy-upstart-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Upstart (NASDAQ:UPST) -- a company that uses artificial intelligence systems to determine would-be borrowers' creditworthiness -- has caught the attention of Wall Street and the mainstream financial ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/15/is-it-too-late-to-buy-upstart-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UPST":"Upstart Holdings, Inc."},"source_url":"https://www.fool.com/investing/2021/10/15/is-it-too-late-to-buy-upstart-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2175485551","content_text":"Upstart (NASDAQ:UPST) -- a company that uses artificial intelligence systems to determine would-be borrowers' creditworthiness -- has caught the attention of Wall Street and the mainstream financial media in 2021. As a result, the stock price has surged more than 1,000% since its December 2020 IPO, raising questions about how much bigger this company can get.\nBut investors considering buying in on Upstart now should remember that this is still a young business, and its stock has the potential to grow another 1,000% over the next decade. The company has just started de-risking itself, making it safer for investors to get a piece of the action.\nLet's go into more detail about why Upstart is still worth buying today.\nImage source: Getty Images.\nUpstart's formula could replace FICO\nFor decades, the chief way banks and others have determined creditworthiness is by looking at a person's FICO score -- a metric created by Fair Isaac Corp. (NYSE:FICO) back in 1989. There are a host of variations based on that model now, but still, those scores have certain weaknesses -- primarily because there are plenty of people who have poor credit histories or no credit history at all, but who would nonetheless be good credit risks. Fully 80% of Americans have never defaulted on a loan payment, yet fewer than half of Americans have prime credit -- meaning that as much as 30% of the populace are potentially good people to lend money to, but might get rejected by banks making their decisions solely by looking at credit scores.\nUpstart looks at a much bigger picture -- everything from employment history to how applicants interact with the loan application -- and takes all of this data into account, determining each consumer's creditworthiness with impressive accuracy. An internal study by Upstart showed that all other things being equal, Upstart's evaluations led to 75% fewer defaults than when relying on traditional models.\nEven better, the more loan decisions it makes, the more accurate Upstart's AI should get. Each borrower it recommends lending to will either pay off their loan or default. If they default, the model will learn that customers with similar traits might also be less likely to pay off loans. That steady aggregation of new data could help it adjust its decision-making and decrease its default rate as time goes on.\nWith Upstart, the process to get a loan is becoming much easier. The company approves an average of 27% more loans than banks do using their traditional model, while applicants get on average a 16% lower interest rate. The decision process is also quick for the customer: Upstart's AI has gotten so good that it has been able to automatically approve 71% of its applications with minimal fraud risk. Among its accepted loan applications in 2020's fourth quarter, only 0.4% later proved to be fraudulent.\nInnovation is leading to success\nReinventing the loan approval process has resulted in strong financial success for Upstart. The company gave its thumbs-up to 24% of the loan applications it saw in Q2 2021, reaching a transaction volume of 287,000 loans. And loan volume increased by 69% from the first quarter.\nRelated to the increase in loan volume, Upstart's Q2 revenue grew by 1,000% year over year, and by 60% sequentially, to $194 million. Its contribution profit -- a metric similar to gross margin -- was 50% of total revenue in Q2, up from 46% in Q1 2021.\nDespite being a small company in terms of revenue, Upstart is profitable. Its net income for Q2 was $37 million, an improvement from its net loss of $6 million in the prior-year quarter. The company also produced free cash flow of $134 million in the first half of 2021 -- representing a free cash flow margin of 44%.\nIt won't be surprising to see this strong growth continue. In addition to the network effects it benefits from, lending is an enormous market. Management sees a market opportunity of $635 billion in auto loan origination and an $84 billion opportunity in personal loans. It's just beginning to tap into the vehicle loan market with its recently launched Upstart Auto Retail product -- an outgrowth of the company's April acquisition of Prodigy, a provider of cloud-based software for auto sales.\nLenders are flocking to Upstart\nLenders are moving to Upstart's platform fast -- four banks have partnered with it since its Q2 report. Its customer concentration was high at the beginning of 2021, with one lender accounting for 67% of its loan volume in 2020. That client only represented 60% of Upstart's loan volume in the first half, however. With the addition of these new banks since it reported Q2 earnings, its concentration figure will likely continue to decline.\nThe stock is trading at 133 times free cash flow and 64 times sales. However, Upstart has been doing everything right so far in 2021: It has decreased its client concentration, expanded into a big new market, and rapidly grown its business. Yet it still has plenty of room for explosive growth over the next 10 years, and investors still have the opportunity to benefit from its game-changing technology.","news_type":1},"isVote":1,"tweetType":1,"viewCount":505,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":822869138,"gmtCreate":1634115143362,"gmtModify":1634115143362,"author":{"id":"3583542338461065","authorId":"3583542338461065","name":"Jerm15","avatar":"https://static.tigerbbs.com/037e3a87ba0e28ca2573a2264ea74e47","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/822869138","repostId":"1126064042","repostType":4,"repost":{"id":"1126064042","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634112106,"share":"https://www.laohu8.com/m/news/1126064042?lang=&edition=full","pubTime":"2021-10-13 16:01","market":"us","language":"en","title":"Apple shares fell nearly  1% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1126064042","media":"Tiger Newspress","summary":"Apple shares fell nearly 1% in premarket trading afte Apple set to cut iPhone production goals due t","content":"<p>Apple shares fell nearly 1% in premarket trading&nbsp;afte&nbsp;Apple set to cut iPhone production goals due to chip crunch.</p>\n<p><img src=\"https://static.tigerbbs.com/59416dec265c2e702b1b0b4cefaedaaa\" tg-width=\"850\" tg-height=\"617\" width=\"100%\" height=\"auto\"></p>\n<p>Apple Inc.&nbsp;is likely to slash its projected iPhone 13 production targets for 2021 by as many as 10 million units as prolonged chip shortages hit its flagship product, according to people with knowledge of the matter.</p>\n<p>The company had expected to produce 90 million new iPhone models in the last three months of the year, but it’s now telling manufacturing partners that the total will be lower because&nbsp;Broadcom Inc.&nbsp;and&nbsp;Texas Instruments Inc.&nbsp;are struggling to deliver enough components, said the people, who asked not to be identified because the situation is private.</p>\n<p>The technology giant is one of the world’s&nbsp;largest&nbsp;chip buyers and sets the annual rhythm for the electronics supply chain. But even with strong buying power, Apple is grappling with the same supply disruptions that have wreaked havoc on industries around the world. Major chipmakers have&nbsp;warned&nbsp;that demand will continue to outpace supply throughout next year and potentially beyond.</p>\n<p>Apple gets display parts from Texas Instruments, while Broadcom is its longtime supplier of wireless components. One TI chip in short supply for the latest iPhones is related to powering the OLED display. Apple also is facing component shortages from other suppliers.</p>\n<p>Apple and TI representatives declined to comment. Broadcom didn’t respond to a request for comment.</p>\n<p><img src=\"https://static.tigerbbs.com/a08c5763a83cf33b076814728233fce2\" tg-width=\"973\" tg-height=\"555\" referrerpolicy=\"no-referrer\"></p>\n<p>Apple shares slipped as much as 1.6% to $139.27 in late trading after Bloomberg reported on the news. The stock was up 6.6% this year through Tuesday’s close. Broadcom and TI also dipped in after-hours trading.</p>\n<p>The shortages have already weighed on Apple’s ability to ship new models to customers. The iPhone 13 Pro and iPhone 13 Pro Max went on sale in September, but orders won’t be delivered from Apple’s website for about a month. And the new devices are listed as “currently unavailable” for pickup at several of the company’s retail stores. Apple’s carrier partners are also seeing similar shipment delays.</p>\n<p>Current orders are slated to ship around mid-November, so Apple could still get the new iPhones to consumers in time for the crucial holiday season. The year-end quarter is expected to be Apple’s biggest sales blitz yet, generating about $120 billion in revenue. That would be up about 7% from a year earlier -- and more money than Apple made in an entire year a decade ago.</p>\n<p>Apple’s woes show that even the king of the tech world isn’t immune from global shortages made worse by the pandemic. In addition to facing tight iPhone availability, the company has struggled to make enough of the Apple Watch Series 7 and other products.</p>\n<p>Earlier this year, Apple warned that it would face supply constraints of the iPhone and iPad during the quarter that ended in September. The Cupertino, California-based company cited the global chip shortages at the time. That period included about a week and a half of iPhone 13 revenue.</p>\n<p>Broadcom doesn’t have major factories of its own and relies on contract chipmakers like&nbsp;Taiwan Semiconductor Manufacturing Co.&nbsp;to build its products. Texas Instruments makes some chips in-house, but also relies on outside manufacturing. That means they’re part of an increasingly challenging fight to secure production capacity at TSMC and other foundries. Apple is a TSMC client itself -- in fact, it’s the company’s largest. Apple uses the manufacturer to make its A-series processors, but they don’t appear to be under threat of shortages for now.</p>\n<p>There are signs the chip crunch is getting worse. Lead times in the industry -- the gap between putting in a semiconductor order and taking delivery -- rose for the ninth month in a row to&nbsp;an average of 21.7 weeks&nbsp;in September, according to Susquehanna Financial Group.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple shares fell nearly  1% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple shares fell nearly  1% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-13 16:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Apple shares fell nearly 1% in premarket trading&nbsp;afte&nbsp;Apple set to cut iPhone production goals due to chip crunch.</p>\n<p><img src=\"https://static.tigerbbs.com/59416dec265c2e702b1b0b4cefaedaaa\" tg-width=\"850\" tg-height=\"617\" width=\"100%\" height=\"auto\"></p>\n<p>Apple Inc.&nbsp;is likely to slash its projected iPhone 13 production targets for 2021 by as many as 10 million units as prolonged chip shortages hit its flagship product, according to people with knowledge of the matter.</p>\n<p>The company had expected to produce 90 million new iPhone models in the last three months of the year, but it’s now telling manufacturing partners that the total will be lower because&nbsp;Broadcom Inc.&nbsp;and&nbsp;Texas Instruments Inc.&nbsp;are struggling to deliver enough components, said the people, who asked not to be identified because the situation is private.</p>\n<p>The technology giant is one of the world’s&nbsp;largest&nbsp;chip buyers and sets the annual rhythm for the electronics supply chain. But even with strong buying power, Apple is grappling with the same supply disruptions that have wreaked havoc on industries around the world. Major chipmakers have&nbsp;warned&nbsp;that demand will continue to outpace supply throughout next year and potentially beyond.</p>\n<p>Apple gets display parts from Texas Instruments, while Broadcom is its longtime supplier of wireless components. One TI chip in short supply for the latest iPhones is related to powering the OLED display. Apple also is facing component shortages from other suppliers.</p>\n<p>Apple and TI representatives declined to comment. Broadcom didn’t respond to a request for comment.</p>\n<p><img src=\"https://static.tigerbbs.com/a08c5763a83cf33b076814728233fce2\" tg-width=\"973\" tg-height=\"555\" referrerpolicy=\"no-referrer\"></p>\n<p>Apple shares slipped as much as 1.6% to $139.27 in late trading after Bloomberg reported on the news. The stock was up 6.6% this year through Tuesday’s close. Broadcom and TI also dipped in after-hours trading.</p>\n<p>The shortages have already weighed on Apple’s ability to ship new models to customers. The iPhone 13 Pro and iPhone 13 Pro Max went on sale in September, but orders won’t be delivered from Apple’s website for about a month. And the new devices are listed as “currently unavailable” for pickup at several of the company’s retail stores. Apple’s carrier partners are also seeing similar shipment delays.</p>\n<p>Current orders are slated to ship around mid-November, so Apple could still get the new iPhones to consumers in time for the crucial holiday season. The year-end quarter is expected to be Apple’s biggest sales blitz yet, generating about $120 billion in revenue. That would be up about 7% from a year earlier -- and more money than Apple made in an entire year a decade ago.</p>\n<p>Apple’s woes show that even the king of the tech world isn’t immune from global shortages made worse by the pandemic. In addition to facing tight iPhone availability, the company has struggled to make enough of the Apple Watch Series 7 and other products.</p>\n<p>Earlier this year, Apple warned that it would face supply constraints of the iPhone and iPad during the quarter that ended in September. The Cupertino, California-based company cited the global chip shortages at the time. That period included about a week and a half of iPhone 13 revenue.</p>\n<p>Broadcom doesn’t have major factories of its own and relies on contract chipmakers like&nbsp;Taiwan Semiconductor Manufacturing Co.&nbsp;to build its products. Texas Instruments makes some chips in-house, but also relies on outside manufacturing. That means they’re part of an increasingly challenging fight to secure production capacity at TSMC and other foundries. Apple is a TSMC client itself -- in fact, it’s the company’s largest. Apple uses the manufacturer to make its A-series processors, but they don’t appear to be under threat of shortages for now.</p>\n<p>There are signs the chip crunch is getting worse. Lead times in the industry -- the gap between putting in a semiconductor order and taking delivery -- rose for the ninth month in a row to&nbsp;an average of 21.7 weeks&nbsp;in September, according to Susquehanna Financial Group.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126064042","content_text":"Apple shares fell nearly 1% in premarket trading afte Apple set to cut iPhone production goals due to chip crunch.\n\nApple Inc. is likely to slash its projected iPhone 13 production targets for 2021 by as many as 10 million units as prolonged chip shortages hit its flagship product, according to people with knowledge of the matter.\nThe company had expected to produce 90 million new iPhone models in the last three months of the year, but it’s now telling manufacturing partners that the total will be lower because Broadcom Inc. and Texas Instruments Inc. are struggling to deliver enough components, said the people, who asked not to be identified because the situation is private.\nThe technology giant is one of the world’s largest chip buyers and sets the annual rhythm for the electronics supply chain. But even with strong buying power, Apple is grappling with the same supply disruptions that have wreaked havoc on industries around the world. Major chipmakers have warned that demand will continue to outpace supply throughout next year and potentially beyond.\nApple gets display parts from Texas Instruments, while Broadcom is its longtime supplier of wireless components. One TI chip in short supply for the latest iPhones is related to powering the OLED display. Apple also is facing component shortages from other suppliers.\nApple and TI representatives declined to comment. Broadcom didn’t respond to a request for comment.\n\nApple shares slipped as much as 1.6% to $139.27 in late trading after Bloomberg reported on the news. The stock was up 6.6% this year through Tuesday’s close. Broadcom and TI also dipped in after-hours trading.\nThe shortages have already weighed on Apple’s ability to ship new models to customers. The iPhone 13 Pro and iPhone 13 Pro Max went on sale in September, but orders won’t be delivered from Apple’s website for about a month. And the new devices are listed as “currently unavailable” for pickup at several of the company’s retail stores. Apple’s carrier partners are also seeing similar shipment delays.\nCurrent orders are slated to ship around mid-November, so Apple could still get the new iPhones to consumers in time for the crucial holiday season. The year-end quarter is expected to be Apple’s biggest sales blitz yet, generating about $120 billion in revenue. That would be up about 7% from a year earlier -- and more money than Apple made in an entire year a decade ago.\nApple’s woes show that even the king of the tech world isn’t immune from global shortages made worse by the pandemic. In addition to facing tight iPhone availability, the company has struggled to make enough of the Apple Watch Series 7 and other products.\nEarlier this year, Apple warned that it would face supply constraints of the iPhone and iPad during the quarter that ended in September. The Cupertino, California-based company cited the global chip shortages at the time. That period included about a week and a half of iPhone 13 revenue.\nBroadcom doesn’t have major factories of its own and relies on contract chipmakers like Taiwan Semiconductor Manufacturing Co. to build its products. Texas Instruments makes some chips in-house, but also relies on outside manufacturing. That means they’re part of an increasingly challenging fight to secure production capacity at TSMC and other foundries. Apple is a TSMC client itself -- in fact, it’s the company’s largest. Apple uses the manufacturer to make its A-series processors, but they don’t appear to be under threat of shortages for now.\nThere are signs the chip crunch is getting worse. Lead times in the industry -- the gap between putting in a semiconductor order and taking delivery -- rose for the ninth month in a row to an average of 21.7 weeks in September, according to Susquehanna Financial Group.","news_type":1},"isVote":1,"tweetType":1,"viewCount":535,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":850719551,"gmtCreate":1634626340644,"gmtModify":1634626340783,"author":{"id":"3583542338461065","authorId":"3583542338461065","name":"Jerm15","avatar":"https://static.tigerbbs.com/037e3a87ba0e28ca2573a2264ea74e47","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/850719551","repostId":"1147398025","repostType":4,"isVote":1,"tweetType":1,"viewCount":599,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":827923049,"gmtCreate":1634393205516,"gmtModify":1634393205661,"author":{"id":"3583542338461065","authorId":"3583542338461065","name":"Jerm15","avatar":"https://static.tigerbbs.com/037e3a87ba0e28ca2573a2264ea74e47","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/827923049","repostId":"2175485551","repostType":4,"isVote":1,"tweetType":1,"viewCount":505,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":822869138,"gmtCreate":1634115143362,"gmtModify":1634115143362,"author":{"id":"3583542338461065","authorId":"3583542338461065","name":"Jerm15","avatar":"https://static.tigerbbs.com/037e3a87ba0e28ca2573a2264ea74e47","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/822869138","repostId":"1126064042","repostType":4,"isVote":1,"tweetType":1,"viewCount":535,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693000140,"gmtCreate":1639916996670,"gmtModify":1639916996729,"author":{"id":"3583542338461065","authorId":"3583542338461065","name":"Jerm15","avatar":"https://static.tigerbbs.com/037e3a87ba0e28ca2573a2264ea74e47","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693000140","repostId":"1122414343","repostType":4,"repost":{"id":"1122414343","pubTimestamp":1639884070,"share":"https://www.laohu8.com/m/news/1122414343?lang=&edition=full","pubTime":"2021-12-19 11:21","market":"us","language":"en","title":"Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade","url":"https://stock-news.laohu8.com/highlight/detail?id=1122414343","media":"Seeking Alpha","summary":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5","content":"<p>The healthcare stocks in the S&amp;P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&amp;A prospects. <a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.</p>\n<p>Among stocks with more than $2B market capitalization and 100K average daily volume over the past week, <a href=\"https://laohu8.com/S/ARNA\">Arena Pharmaceuticals </a> dominated with a ~83.8% rise after <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. <a href=\"https://laohu8.com/S/CERN\">Cerner </a> also joined the M&amp;A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from <a href=\"https://laohu8.com/S/ORCL\">Oracle </a> for the electronic-medical-records company.</p>\n<p>Vaccine developer, <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.</p>\n<p><a href=\"https://laohu8.com/S/BHVN\">Biohaven Pharmaceutical </a> posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, <a href=\"https://laohu8.com/S/ROIV\">Roivant Sciences </a> added ~22.6%.</p>\n<p>Notable gainer: <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the <a href=\"https://laohu8.com/S/NWY\">New York</a>-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.</p>\n<p>Among worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.</p>\n<p>Last week’s best performer, <a href=\"https://laohu8.com/S/BHG\">Bright Health Group</a>, crashed ~13.1%, hurt by the sole Sell rating issued by <a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a> even as the investment bank kicked off its coverage on managed care with largely positive views.</p>\n<p>Allogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic <a href=\"https://laohu8.com/S/00699\">CAR</a> T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax, Vir among healthcare gainers, Pfizer posts best rally in a decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-19 11:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the ...</p>\n\n<a href=\"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ORCL":"甲骨文","BK4534":"瑞士信贷持仓","CERN":"美国塞纳","BK4568":"美国抗疫概念","ARNA":"阿里那","PFE":"辉瑞","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药"},"source_url":"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122414343","content_text":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.\nAmong stocks with more than $2B market capitalization and 100K average daily volume over the past week, Arena Pharmaceuticals  dominated with a ~83.8% rise after Pfizer  agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. Cerner  also joined the M&A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from Oracle  for the electronic-medical-records company.\nVaccine developer, Novavax  jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.\nBiohaven Pharmaceutical  posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, Roivant Sciences  added ~22.6%.\nNotable gainer: Pfizer (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the New York-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.\nAmong worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.\nLast week’s best performer, Bright Health Group, crashed ~13.1%, hurt by the sole Sell rating issued by Goldman Sachs even as the investment bank kicked off its coverage on managed care with largely positive views.\nAllogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic CAR T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.","news_type":1},"isVote":1,"tweetType":1,"viewCount":418,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699336409,"gmtCreate":1639747717246,"gmtModify":1639747717246,"author":{"id":"3583542338461065","authorId":"3583542338461065","name":"Jerm15","avatar":"https://static.tigerbbs.com/037e3a87ba0e28ca2573a2264ea74e47","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699336409","repostId":"1116116501","repostType":4,"isVote":1,"tweetType":1,"viewCount":372,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690938709,"gmtCreate":1639620105596,"gmtModify":1639620241947,"author":{"id":"3583542338461065","authorId":"3583542338461065","name":"Jerm15","avatar":"https://static.tigerbbs.com/037e3a87ba0e28ca2573a2264ea74e47","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690938709","repostId":"1139620589","repostType":4,"repost":{"id":"1139620589","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1639617287,"share":"https://www.laohu8.com/m/news/1139620589?lang=&edition=full","pubTime":"2021-12-16 09:14","market":"us","language":"en","title":"Option Traders Bullish On Ford Heading Into 2022 With Strong Upside Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1139620589","media":"Benzinga","summary":"Ford Motor Company is having an impressive year, up over 125% year-to-date and sitting just below th","content":"<p><b>Ford Motor Company</b>&nbsp;is having an impressive year, up over 125% year-to-date and sitting just below the $20 level heading into the holidays.</p>\n<p>Even with such a strong year in 2021, option traders are bullish on Ford heading into the new year, both in the short and long term.</p>\n<p>Looking at the shorter-term Jan. 21 expiry for next year, there has been a lot of call buying at the $20 strike, with over 17,000 options traded at that strike Wednesday. This is combined with the strong open interest at the $20 and $25 strikes with 204,000-plus&nbsp;options at the $20 STR and 135,000-plus&nbsp;at the $22 strike (image below).</p>\n<p><img src=\"https://static.tigerbbs.com/65137fb8894105f2ab49d5bb60db3ae6\" tg-width=\"1114\" tg-height=\"446\" width=\"100%\" height=\"auto\"></p>\n<p><b>Why It Matters:</b>The heavy amount of volume and open interest will create liquidity at those strikes and could pull the stock to these&nbsp;upside targets for the Jan. 21 expiry next year.</p>\n<p>While a portion of the $20 strikes could be call sellers collecting premium on their long stock holdings, it's less likely for the $22&nbsp;strikes considering the premium is so low at 54 cents. Hence, it is more probable the open interest at the $22 strike is long calls.</p>\n<p><b>What's Next:</b>In the short term and into the Jan. 21 expiry for next year, Ford option traders are expecting a move above the $20 strike and potentially up to the $22 strike.</p>\n<p>This bullish sentiment in the option flows is also captured in the Jan. 20 expiry for 2023, with heavy open interest at the $20 and $25 strikes with a potential \"moonshot\"&nbsp;target of $30 by the first month in 2023 (image below).</p>\n<p><img src=\"https://static.tigerbbs.com/807061111a55fee75ede75b4b967a6e6\" tg-width=\"1119\" tg-height=\"346\" width=\"100%\" height=\"auto\"></p>\n<p>Meanwhile, should the stock head lower, there is strong volume and open interest between the $15 and $20 strikes, which could be potentially good levels for dip buying.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Option Traders Bullish On Ford Heading Into 2022 With Strong Upside Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOption Traders Bullish On Ford Heading Into 2022 With Strong Upside Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-16 09:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Ford Motor Company</b>&nbsp;is having an impressive year, up over 125% year-to-date and sitting just below the $20 level heading into the holidays.</p>\n<p>Even with such a strong year in 2021, option traders are bullish on Ford heading into the new year, both in the short and long term.</p>\n<p>Looking at the shorter-term Jan. 21 expiry for next year, there has been a lot of call buying at the $20 strike, with over 17,000 options traded at that strike Wednesday. This is combined with the strong open interest at the $20 and $25 strikes with 204,000-plus&nbsp;options at the $20 STR and 135,000-plus&nbsp;at the $22 strike (image below).</p>\n<p><img src=\"https://static.tigerbbs.com/65137fb8894105f2ab49d5bb60db3ae6\" tg-width=\"1114\" tg-height=\"446\" width=\"100%\" height=\"auto\"></p>\n<p><b>Why It Matters:</b>The heavy amount of volume and open interest will create liquidity at those strikes and could pull the stock to these&nbsp;upside targets for the Jan. 21 expiry next year.</p>\n<p>While a portion of the $20 strikes could be call sellers collecting premium on their long stock holdings, it's less likely for the $22&nbsp;strikes considering the premium is so low at 54 cents. Hence, it is more probable the open interest at the $22 strike is long calls.</p>\n<p><b>What's Next:</b>In the short term and into the Jan. 21 expiry for next year, Ford option traders are expecting a move above the $20 strike and potentially up to the $22 strike.</p>\n<p>This bullish sentiment in the option flows is also captured in the Jan. 20 expiry for 2023, with heavy open interest at the $20 and $25 strikes with a potential \"moonshot\"&nbsp;target of $30 by the first month in 2023 (image below).</p>\n<p><img src=\"https://static.tigerbbs.com/807061111a55fee75ede75b4b967a6e6\" tg-width=\"1119\" tg-height=\"346\" width=\"100%\" height=\"auto\"></p>\n<p>Meanwhile, should the stock head lower, there is strong volume and open interest between the $15 and $20 strikes, which could be potentially good levels for dip buying.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"F":"福特汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139620589","content_text":"Ford Motor Company is having an impressive year, up over 125% year-to-date and sitting just below the $20 level heading into the holidays.\nEven with such a strong year in 2021, option traders are bullish on Ford heading into the new year, both in the short and long term.\nLooking at the shorter-term Jan. 21 expiry for next year, there has been a lot of call buying at the $20 strike, with over 17,000 options traded at that strike Wednesday. This is combined with the strong open interest at the $20 and $25 strikes with 204,000-plus options at the $20 STR and 135,000-plus at the $22 strike (image below).\n\nWhy It Matters:The heavy amount of volume and open interest will create liquidity at those strikes and could pull the stock to these upside targets for the Jan. 21 expiry next year.\nWhile a portion of the $20 strikes could be call sellers collecting premium on their long stock holdings, it's less likely for the $22 strikes considering the premium is so low at 54 cents. Hence, it is more probable the open interest at the $22 strike is long calls.\nWhat's Next:In the short term and into the Jan. 21 expiry for next year, Ford option traders are expecting a move above the $20 strike and potentially up to the $22 strike.\nThis bullish sentiment in the option flows is also captured in the Jan. 20 expiry for 2023, with heavy open interest at the $20 and $25 strikes with a potential \"moonshot\" target of $30 by the first month in 2023 (image below).\n\nMeanwhile, should the stock head lower, there is strong volume and open interest between the $15 and $20 strikes, which could be potentially good levels for dip buying.","news_type":1},"isVote":1,"tweetType":1,"viewCount":536,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607427370,"gmtCreate":1639580437231,"gmtModify":1639580437308,"author":{"id":"3583542338461065","authorId":"3583542338461065","name":"Jerm15","avatar":"https://static.tigerbbs.com/037e3a87ba0e28ca2573a2264ea74e47","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607427370","repostId":"1148643584","repostType":4,"isVote":1,"tweetType":1,"viewCount":433,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603245862,"gmtCreate":1638418618759,"gmtModify":1638418618874,"author":{"id":"3583542338461065","authorId":"3583542338461065","name":"Jerm15","avatar":"https://static.tigerbbs.com/037e3a87ba0e28ca2573a2264ea74e47","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603245862","repostId":"1182613816","repostType":4,"isVote":1,"tweetType":1,"viewCount":838,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841511031,"gmtCreate":1635924404437,"gmtModify":1635924404437,"author":{"id":"3583542338461065","authorId":"3583542338461065","name":"Jerm15","avatar":"https://static.tigerbbs.com/037e3a87ba0e28ca2573a2264ea74e47","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841511031","repostId":"1127572635","repostType":4,"isVote":1,"tweetType":1,"viewCount":368,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}